Long‐Circulating and Passively Tumor‐Targeted Polymer‐Drug Conjugates Improve the Efficacy and Reduce the Toxicity of Radiochemotherapy
Source abstract
Abstract
Using HPMA copolymers as a model drug carrier, and doxorubicin and gemcitabine as model drugs, we here show that long-circulating and passively tumor-targeted polymeric drug carriers interact synergistically with radiotherapy, with radiotherapy improving the tumor accumulation of the copolymers, and with the copolymers improving both the efficacy and the toxicity of radiochemotherapy. These findings indicate that “carrier-based radiochemotherapy” holds significant potential for improving the treatment of advanced solid malignancies. The combination of radiotherapy and chemotherapy has been evaluated extensively in the past few decades.1, 2 Besides significantly increasing the efficacy of radiotherapy, however, the simultaneous application of chemotherapy generally also substantially increases its toxicity. As radiotherapy can nowadays be delivered with extremely high levels of spatial specificity, this is likely mostly due to the low degree of spatial specificity that chemotherapeutic agents generally present upon intravenous (i.v.) administration. Based on this notion, and on the fact that drug targeting systems are known to be able to improve both the temporal (i.e., circulation time and tumor residence time) and the spatial (i.e., tumor accumulation and tumor-to-organ ratio) parameters of conjugated or entrapped active agents,3-6 we have set out to evaluate the potential of combining long-circulating and passively tumor-targeted polymeric prodrugs with clinically relevant regimens of fractionated radiotherapy. The rationale for this novel combination regimen, which we have termed “carrier-based radiochemotherapy,”7 relies on the notion that radiotherapy and drug targeting systems interact synergistically (Fig. 1A). On the one hand, by means of several different physiological mechanisms, like vascular endothelial growth factor (VEGF) expression, apoptosis induction and interstitial fluid pressure (IFP) reduction, radiotherapy is able to increase the tumor localization of drug targeting systems. On the other hand, by means of their prolonged circulation times and enhanced tumor accumulation, drug targeting systems are able to improve the interaction between systemically applied chemotherapy and clinically relevant fractionated radiotherapy, which is routinely applied on every weekday for several consecutive weeks (Fig. 1B). As will be outlined below, evidence has been obtained for both arms of carrier-based radiochemotherapy, and both for doxorubicin and for gemcitabine, drug targeting increased the efficacy of radiochemotherapy without increasing its toxicity. Rationale for carrier-based radiochemotherapy. (A) Carrier-based radiochemotherapy relies on the notion that drug targeting systems and radiotherapy interact synergistically, with on the one hand, radiotherapy improving the tumor accumulation of drug targeting systems, and with on the other hand, drug targeting systems improving the temporal and spatial interaction between i.v. applied (weekly) chemotherapy and clinically relevant (daily) radiotherapy. (B) Schematic representation of the in vivo interaction between daily radiotherapy and weekly chemotherapy upon standard radiochemotherapy and upon carrier-based radiochemotherapy, exemplifying that in case of the latter, both the temporal and the spatial interaction between the two treatment modalities is improved. The biodistribution of an intravenously applied standard (left panel) and passively tumor-targeted (right panel) chemotherapeutic agent is depicted in red, the application of fractionated radiotherapy in yellow (lightning), and tumors as squares. Adapted, with permission, from ref.7 The copolymers used in this study were synthesized as described previously.8-11 Briefly, poly[N-2-hydroxypropyl)methacrylamide-co-methacryloyltyrosinamide] [poly(HPMA-co-MA-TyrNH2)] was prepared by solution radical copolymerization of the monomers HPMA and MA-TyrNH2. The average molecular weights of the three TyrNH2-modified HPMA copolymers (as determined by size exclusion chromatography) were 23.4, 30.5, and 64.5 kDa, their polydispersities were 1.4, 1.3, and 1.2, and the relative amounts of TyrNH2, included to allow for radiolabeling, were 0.4, 0.8, and 1.1 mol%. The precursor for the HPMA copolymer conjugate bearing doxorubicin via the degradable glycyl-DL-phenylalanylleucylglycyl spacer, i.e., poly-(HPMA-co-MA-GFLG-ONp), was prepared by precipitation radical copolymerization of HPMA and MA-GFLG-ONp. After purification, doxorubicin was conjugated to this precursor in DMSO, in the presence of Et3N. After removal of EtN3·HCl and precipitation into acetone-dietlylether, the resulting doxorubicin-containing conjugate was then filtered off, dried in vacuum, purified on a Sephadex LH-20 column (to remove free doxorubicin), and fractionated on an LH-60 column (to obtain a narrow distribution of the molecular weight). The average molecular weight of poly(HPMA)-GFLG-Dox was 27.9 kDa, its polydispersity was 1.5, and the amount of doxorubicin was 6.5 wt%. Comparable methods, but different precursors [i.e., containing thiazolidine-2-thione imide (TT) reactive groups] were used to generate two gemcitabine-containing copolymers.7 The average molecular weights of A-Gem [i.e., the HPMA copolymer conjugate bearing gemicitabine (Gem) bound via the nondegradable aminohexanoyl (AH) spacer] and of B-Gem [i.e., the HPMA copolymer conjugate bearing gemicitabine bound via the enzymatically cleavable GFLC spacer] were 20.2 and 24.0 kDa, their polydispersities were 1.5 and 1.6, and their drug contents were 6.8 and 10.9 wt%, respectively. Iodine-131 was obtained from Amersham (Freiburg, Germany). The TyrNH2 groups incorporated into the copolymers were radiolabeled using the Iodogen method.12 After 10 min of incubation, the mixture of iodine-131, Iodogen, and the copolymer was applied to a Biogel-P6 column and it was eluted with 30 mL of PBS. The eluate was recovered in 1 mL fractions and the radioactivity of each of these fractions was determined by means of a scintillation counter. The radiolabeled copolymer was retrieved in the fifth to seventh milliliter of the eluate, while free (i.e., unbound) iodine-131 was eluted in the fourteenth to eighteenth milliliter. As this methodology allowed us to concentrate the copolymer-associated fraction, no additional purification was required. The efficacy of radiolabeling was quantified by dividing the amount of radioactivity collected in the fifth to seventh milliliter of the eluate by the total amount of radioactivity retrieved, i.e., by the sum of the activities detected in all thirty 1 mL fractions. In all cases, labeling efficacies were well above 95%. For analyzing the pharmacokinetics and the biodistribution of the copolymers, 500 µL of a 0.1 mM solution (based on copolymer concentration, and corresponding to a radioactivity of 150–300 µCi) were injected i.v. into the lateral tail vein of tumor-bearing rats. At several different time points after i.v. injection, the biodistribution of the copolymers was monitored using a Searle-Siemens scintillation camera, and 20–50 µL of blood were withdrawn to determine their concentrations in blood. The amounts of radiolabeled copolymer in systemic circulation were approximated by assuming that the complete blood pool equals 6% of the body weight of the rats. One week after i.v. injection, the animals were sacrificed, and tumors and organs were collected. Residual amounts of radioactivity in dissected tissues were determined using a gamma counter (Canberra Packard), they were corrected for radioactive decay, and they were expressed as percent of the injected dose per gram tissue (% ID/g). All experiments involving animals were approved by an external committee for animal welfare and were performed according to the guidelines for laboratory animals established by the German government. Experiments were performed on 6–12 month old male Copenhagen rats, using the syngeneic and radio- and chemoresistant Dunning AT1 prostate carcinoma model. Fresh pieces (∼10 mm3) of an AT1 donor tumor were transplanted subcutaneously into both hind limbs of the animals. Prior to the treatment, tumors were grown for 6–8 days, until they reached an average diameter of 6 mm. Doxorubicin was administered at its maximum tolerated dose (MTD), i.e., at three doses of 2.5 mg kg−1 (day 1, 8, and 15). PK1, i.e., poly(HPMA-GFLG- doxorubicin), was applied at three doxorubicin- equivalent doses of 5 mg kg−1. Local external beam radiotherapy was delivered by means of the Siemens Gammatron S, and it was applied at a regimen comparable to that routinely used in clinics: 2 Gy was given on every weekday for four consecutive weeks, i.e., for a total of 20 doses of 2 Gy. Gemcitabine and the gemcitabine-containing copolymers were administered four times, at a dose of 3 mg kg−1 (day 1, 8, 15, and 22). In this case, radiotherapy was given three times weekly for 4 weeks, at a dose of 3 Gy, i.e., for a total of 12 doses of 3 Gy. Tumor volumes were calculated using the formula , and they were expressed relative to the volume determined on the first day of therapy. The toxicity of the combination regimens was assessed by determining the (relative) body weight loss of the animals. Values are expressed as average ± standard deviation. In the pharmacokinetic and biodistributional analyses, the two-tailed t-test was used. In the therapeutic analyses, the Mann–Whitney U test (i.e., Wilcoxon Rank-Sum) was used. Bonferroni–Holm post hoc analysis was used to correct for multiple comparisons. In all cases, p < 0.05 was considered to represent statistical significance. To evaluate the pharmacokinetics, the tumor accumulation and the organ distribution of HPMA copolymers, we first radiolabeled three differently sized TyrNH2-modified copolymers (23, 31, and 65 kDa; see Fig. 2) with iodine-131. Blood samples were withdrawn at several different time points after i.v. injection, and 2D γ-scintigraphy was used to monitor their biodistribution.8 As shown in Figure 3A, all three copolymers circulated for prolonged periods of time, with throughout follow-up, significantly higher levels were present in systemic circulation than for the i.v. applied free label (i.e., iodine-131). At 24 h post i.v. injection, for instance, 24, 11, and 6% of the injected dose were still present in blood for the 65, 31, and 23 kDa copolymer, respectively, as compared to less than 0.0001% for the free label. HPMA copolymers circulate for prolonged periods of time, and localize to tumors both effectively and selectively. (A) Blood concentration versus time curves of three differently sized tyrosinamide-modified and iodine-131-labeled HPMA copolymers upon i.v. injection into Copenhagen rats bearing subcutaneously transplanted Dunning AT1 tumors, exemplifying that they are retained in systemic circulation significantly more effective than is the free label (i.e., free iodine-131). (B) Schematic representation of the regions of interest and the corresponding organs used in the scintigraphic analyses. (C) Biodistribution of the three radiolabeled copolymers mentioned above, visualized using 2D γ-scintigraphy, showing that they effectively localize to tumors over time. (D) Analysis of the tumor and organ concentrations of six differently sized HPMA copolymers at 168 h after i.v. injection, exemplifying selective tumor accumulation. Except for spleen, the levels of the copolymers in tumors were always significantly higher than their levels in the majority of healthy tissues. (E) Fluorescence microscopy analysis of the amount of doxorubicin localized to AT1 tumors at 24 h p.i. (F) HPLC analysis of the amount of doxorubicin in tumors at 24 p.i., exemplifying the beneficial effect of drug targeting. Adapted, with permission, from ref.7, 8, 12. Structures and characteristics of the copolymers used in this study. (A–D) Chemical structures of TyrNH2-modified of HPMA doxorubicin and of two different of HPMA gemcitabine and (D) and (E) of the copolymers mentioned TyrNH2, glycyl-DL-phenylalanylleucylglycyl (i.e., a drug (i.e., drug molecular weight polydispersity (i.e., To the biodistribution and the tumor accumulation of the three copolymers, scintigraphic were obtained at 24, and 168 h p.i. In Figure for a of the several regions of interest and the corresponding organs are and in Figure biodistributional are for the 31, and 65 kDa can be in the that by means of the enhanced and the copolymers in tumors both effectively and selectively. can also be that in with their circulation times with drug targeting to the tumor accumulation of the copolymers well with their with higher average molecular weights resulting in higher tumor As shown in Figure of the tumor and organ concentrations of six differently sized HPMA copolymers at 168 h p.i. the above the concentrations of the copolymers in tumors were always to be significantly higher than their levels in the majority of healthy that their tumor accumulation was effective and in the spleen, which is known to be in the of long-circulating from the the concentrations of the copolymers were always to be significantly higher than in in with effective drug targeting to tumors, Figure that the tumor concentrations of HPMA copolymers well with their average molecular for 31, and 65 kDa for instance, levels in tumors were 0.4, and of the injected dose per gram 12 Using microscopy and it was also that by means of their beneficial HPMA copolymers are able to improve the of increasing its accumulation at 24 h p.i. by more than a (Fig. and these findings show that HPMA copolymers circulate for prolonged periods of time, that they localize to tumors both effectively and and that they are able to improve the of low molecular weight exemplifying that HPMA copolymers are systems for the and the therapeutic potential of carrier-based radiochemotherapy. to evidence for the first of carrier-based radiochemotherapy, i.e., to evaluate radiotherapy is able to improve the tumor accumulation of HPMA copolymers, the tumor-bearing limbs of the animals were to 2 and 20 Gy of 1 and 24 h their i.v. As shown in the in Figure a 20 Gy dose of radiotherapy applied 24 h to i.v. injection increased the tumor accumulation of the kDa copolymer in two different tumor and both at 4 and at 24 h p.i. as to for which in the model (i.e., a of the Dunning prostate which as to the well blood an increase was In with the concentrations of the and 65 kDa copolymer were quantified at 24 h p.i., radiotherapy was to improve the tumor accumulation of the copolymers of the tumor model used (Fig. and 20 Gy dose of radiotherapy applied 24 h to i.v. injection, for instance, increased the concentration of kDa in tumors from ± to ± in tumors from ± to ± and in tumors from ± to ± For 65 kDa 20 Gy of radiotherapy applied 24 h to i.v. injection increased the concentration of the copolymer in tumors from ± to ± and in tumors from ± to ± drug targeting. (A) analysis of the of radiotherapy 24 h to i.v. and applied for 1 to i.v. on the tumor accumulation of the radiolabeled HPMA (B) and (C) Analysis of the effect of different doses of radiotherapy on the tumor accumulation of the kDa (B) and the 65 kDa (C) copolymer at 24 h after i.v. injection, exemplifying that radiotherapy the tumor accumulation of HPMA copolymers of the tumor model used. Values represent average ± p < Adapted, with permission, from In these findings were and that also at 168 h after i.v. injection, the levels of the copolymers were significantly higher in tumors than in In to in the we also used to the beneficial of radiotherapy on the tumor accumulation of the copolymers, in to in on the first 24 h after In with obtained using radiolabeled copolymers, these that a HPMA more effectively localized to tumors than to tumors, and that this effect on in time (i.e., at 30 min and until 24 enhanced localization of HPMA copolymers to tumors be using both microscopy and and both for doxorubicin and for it be that in this case, of the high between the were of As it was that radiotherapy the tumor accumulation of HPMA copolymers of the tumor model used (as to see Fig. and it is to that radiotherapy drug targeting to tumors by one or more physiological is known in this for instance, that radiotherapy the of is also known as i.e., vascular and its has been with an increased vascular The holds for growth factor which is also in to and which also increases vascular In to radiotherapy has been shown to the in solid The is a of solid that to an pressure tumors and that at in for the of agents in a time radiotherapy has been shown to be able to the tumor in which is also known to be an of the degree of drug into solid at higher doses (i.e., endothelial apoptosis can also be to a in determining the degree of upon the of carrier-based radiochemotherapy, i.e., the that drug targeting systems are able to improve the interaction between i.v. applied weekly chemotherapy and clinically relevant daily radiotherapy, we have significant in that drug targeting systems are able to improve the therapeutic of radiochemotherapy. The rationale for the of carrier-based radiochemotherapy is depicted in Figure and can be as drug targeting systems are generally to be in and to the conjugated or entrapped active agent at the As a as compared to an i.v. applied free drug has a high concentration, which all over the and which is see in Fig. the concentration of a tumor-targeted agent to be and the degree of systemic toxicity can be For for instance, both and drug targeting systems have been shown to be able to the of At the time, by increasing the concentration of the active agent at the drug targeting systems also to be able to improve the efficacy of the As a of as depicted in the in Figure the of a drug targeting generally increases the concentration of the active agent at the but it also its over time (i.e., its as a of combining a clinically relevant regimen of (weekly) chemotherapy with a clinically relevant regimen of (daily) radiotherapy, it can be that a drug delivered to the tumor by means of a drug targeting more effectively with radiotherapy than a drug (Fig. 1B). To for the above we compared the potential of free doxorubicin to that of HPMA HPMA doxorubicin is also known as PK1, it has been in several and it has been shown to be at effective as free As the of is known to be four to times higher than that of free doxorubicin in and in in an to increase the efficacy and the toxicity of the we to at three times 5 mg kg−1 (day 1, 8, and i.e., at the dose used for free doxorubicin has a of mg kg−1 in was administered at a regimen comparable to that routinely used in clinics: 2 Gy was given on every weekday for four consecutive weeks, i.e., for a total of 20 doses of 2 Gy. combining radiotherapy with we first that in the tumor model i.e., in and radio- and chemoresistant Dunning AT1 tumors, free doxorubicin and HPMA doxorubicin were effective (Fig. agents significantly improve growth as compared to < but the was as by a of the (i.e., the time by tumors to times the volume determined on the first day of of 5 days, from for to for both free doxorubicin and (Fig. In with rationale outlined above, however, and as by Figure with a clinically relevant regimens of radiotherapy (i.e., with 20 daily doses of 2 out to be significantly more effective than free doxorubicin (Fig. and The for was days, as compared to for doxorubicin and to for As a of the factor i.e., a routinely used for determining the potential of chemotherapeutic was significantly higher for than for free i.e., versus at the time, it was also that was significantly less than the free as by the fact that animals with the to weight after the of with free doxorubicin to (Fig. as the efficacy of the be increased while its toxicity be these findings were considered to be an for the fact that drug targeting systems are able to improve the therapeutic of radiochemotherapy. targeting radiochemotherapy. (A) of Dunning AT1 tumors by three i.v. (day 1, 8, and of of free doxorubicin and of HPMA Values represent average ± p < 0.05 versus (B) combining three weekly i.v. (day 1, 8, and of free doxorubicin and HPMA doxorubicin with 20 daily doses of fractionated radiotherapy the passively tumor-targeted polymeric was to be significantly more effective in tumor growth than the free Values represent average ± p < 0.05 versus radiotherapy and p < 0.05 versus radiotherapy free doxorubicin U Bonferroni–Holm post hoc (C) at day of tumors with radiotherapy with free doxorubicin radiotherapy, and with HPMA doxorubicin radiotherapy. (D) loss by the combination showing that the polymeric is significantly less than the free Values represent average ± p < 0.05 versus radiotherapy and p < 0.05 versus radiotherapy HPMA doxorubicin U Bonferroni–Holm post hoc Adapted, with permission, from ref.7 To additional evidence for the of carrier-based radiochemotherapy, we also evaluated the potential of HPMA Gemcitabine is a and it is used in the treatment of advanced solid malignancies. different gemcitabine-containing copolymers were i.e., A-Gem and In the drug is conjugated to the copolymer by means of the (Fig. and in gemcitabine is to the polymeric by means of the spacer, which is also used in and which is known to be by the (Fig. first that A-Gem the drug in than in and that B-Gem in 6 and that B-Gem is more effective in tumor than is the efficacy of these agents in it was that without radiotherapy, the free its polymeric prodrugs were able to growth in the and Dunning AT1 tumor B-Gem applied at four 3 mg kg−1 doses to be the regimen that was significantly more effective than but it was more effective than free gemcitabine Fig. In with however, and to the obtained for upon combining the agents with a clinically relevant regimen of fractionated radiotherapy (i.e., with 12 doses of 3 it be that the was significantly more effective than the free drug (Fig. for a of was as compared to a of for free gemcitabine also that the combination of B-Gem with fractionated radiotherapy was as the combination of free gemcitabine with fractionated radiotherapy, with both agents an degree of weight and comparable levels of In with the obtained for these findings that drug targeting systems are able to increase the efficacy of radiochemotherapy without increasing its toxicity. targeting radiochemotherapy. (A) of Dunning AT1 tumors by four i.v. (day 1, 8, 15, and of of free gemcitabine and of HPMA Values represent average ± p < 0.05 versus (B) Tumor growth by four i.v. (day 1, 8, 15, and of the chemotherapeutic agents in combination with a clinically relevant regimen of fractionated radiotherapy Gy 3 the beneficial effect of drug targeting on the efficacy of radiochemotherapy. Values represent average ± p < 0.05 versus radiotherapy p < versus and p < 0.05 versus free gemcitabine U Bonferroni–Holm post hoc Adapted, with permission, from ref.7 The above and the rationale are in with the of a in which 12 with localized and were with the combination of 6 and fractionated radiotherapy and in which four complete and an additional in tumor size of more than were Prior to this as a a i.v. injection of was with a dose of radiotherapy, for instance, the dose to tumor be from to Gy, and radiotherapy was delivered as daily the effect of was more the from to In a study in the tumor were for i.e., for which also both with dose and with fractionated radiotherapy, and which increase tissue targeting systems are for improving the biodistribution of systemically applied that the temporal and spatial interaction between i.v. applied weekly chemotherapy and clinically relevant daily radiotherapy is and that drug targeting systems are able to improve the temporal and spatial parameters of this we have here set out to evaluate the potential of carrier-based radiochemotherapy. Using HPMA copolymers as a model drug targeting and doxorubicin and gemcitabine as model drugs, we have been able to show that drug targeting systems and radiotherapy interact synergistically, with radiotherapy improving the tumor accumulation of the copolymers, and with the copolymers improving both the efficacy and the toxicity of radiochemotherapy. be in a and tumor and both for doxorubicin and for gemcitabine, that carrier-based radiochemotherapy is a for improving the efficacy of therapy. have in this by to the of carrier-based radiochemotherapy, by clinically relevant regimens of radio- and and by the potential of polymeric prodrugs to that of free chemotherapeutic In the and the evidence obtained that carrier-based radiochemotherapy holds significant potential for improving the treatment of advanced solid malignancies. described in this is on a given at the on in in and was by the in by the by the of of the of and of the and by the and are for
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Nanoplatforms for cancer theranostics · Radiation Therapy and Dosimetry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (39)
Show source-provided references
1. 10.1038/ncponc071410.1038/ncponc0714 ↗
2. 10.1038/nrc145110.1038/nrc1451 ↗
3. 10.1016/S1535-6108(03)00276-910.1016/S1535-6108(03)00276-9 ↗
4. 10.1038/nrd163210.1038/nrd1632 ↗
5. 10.1038/nrc195810.1038/nrc1958 ↗
6. 10.1038/sj.bjc.660448310.1038/sj.bjc.6604483 ↗
7. 10.1038/sj.bjc.660456110.1038/sj.bjc.6604561 ↗
8. 10.1016/j.jconrel.2005.09.01010.1016/j.jconrel.2005.09.010 ↗
9. 10.1593/neo.0643610.1593/neo.06436 ↗
10. 10.1016/j.biomaterials.2009.02.04010.1016/j.biomaterials.2009.02.040 ↗
11. 10.1016/0003-2697(81)90703-X10.1016/0003-2697(81)90703-X ↗
12. Kissel M. · PDA J. Pharm. Sci. Technol. · 2001 · 55 · 191
13. 10.1016/S0168-3659(99)00248-510.1016/S0168-3659(99)00248-5 ↗
14. 10.1016/j.jconrel.2006.10.03210.1016/j.jconrel.2006.10.032 ↗
15. 10.1021/bc050190910.1021/bc0501909 ↗
16. 10.1038/sj.onc.120425810.1038/sj.onc.1204258 ↗
17. Dvorak H. F. · Am. J. Pathol. · 1995 · 146 · 1029
18. 10.1074/jbc.270.48.2879010.1074/jbc.270.48.28790 ↗
19. Samaniego F. · Am. J. Pathol. · 1998 · 152 · 1433
20. Znati C. A. · Cancer Res. · 1996 · 56 · 964
21. Netti P. A. · Cancer Res. · 1995 · 55 · 5451
22. Peschke P. · Histol. Histopathol. · 1999 · 14 · 461
23. 10.1016/S0168-3659(01)00308-X10.1016/S0168-3659(01)00308-X ↗
24. 10.1038/bjc.1997.11910.1038/bjc.1997.119 ↗
25. 10.1126/science.108250410.1126/science.1082504 ↗
26. 10.1007/BF0068731810.1007/BF00687318 ↗
27. 10.1053/j.seminoncol.2004.08.00610.1053/j.seminoncol.2004.08.006 ↗
28. Vasey P. A. · Clin. Cancer Res. · 1999 · 5 · 83
29. 10.1016/S0939-6411(00)00075-810.1016/S0939-6411(00)00075-8 ↗
30. 10.2174/138920103348971110.2174/1389201033489711 ↗
31. Bilim V. · Curr. Opin. Mol. Ther. · 2003 · 5 · 326
32. 10.3892/ijo_0000029310.3892/ijo_00000293 ↗
33. Lawrence T. S. · Semin. Oncol. · 1997 · 24 · S7
34. Lammers T. · Adv. Drug Deliv. Rev. · 2010
35. 10.1097/01.coc.0000224494.07907.4e10.1097/01.coc.0000224494.07907.4e ↗
36. 10.1016/S0360-3016(02)04153-610.1016/S0360-3016(02)04153-6 ↗
37. 10.1158/1078-0432.CCR-06-253410.1158/1078-0432.CCR-06-2534 ↗
38. 10.1016/j.addr.2009.05.00710.1016/j.addr.2009.05.007 ↗
39. 10.1016/j.addr.2009.12.00410.1016/j.addr.2009.12.004 ↗